Economic considerations in the carre of lung cancer patients

Current Opinion in Oncology

Volumn 8, Issue 2, 1996, Pages 126-132

  Desch, Christopher E ^a   Hillner, Bruce E ^b   Smith, Thomas J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Division of General Internal Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FUROSEMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MANNITOL; NAVELBINE; POTASSIUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE; VINDESINE; ZIDOVUDINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PREVENTION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

CLINICAL TRIALS; COST CONTROL; COST-BENEFIT ANALYSIS; HUMANS; LUNG NEOPLASMS; PUBLIC HEALTH; RISK FACTORS;

EID: 0029889825     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199603000-00009     Document Type: Article

References (39)

1. Weeks J, Tierney MR, Weinstein MC: Cost-effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991, 325:81-86.
2. Eddy DM: Rationing resources while improving quality: how to get more for less. JAMA 1994, 272:817-824.
3. Williams AAF, Begley CE: The cost of cancer in Texas. Ten Medicine 1992, 88:62-67.
4. Carbone DP: Chemotherapy for non-small cell lung cancer. BMJ 1995, 311:889-890.
5. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995, 311:899-909. This article provides the most up-to-date meta-analysis of the usefulness of chemotherapy for non-small cell lung cancer. Individual patient data is used, which makes the results very strong. Nevertheless, the survival benefit is small for patients treated aggressively.
6. Is chemotherapy for metastatic nonsmall-cell lung cancer worth it? J Clin Oncol 1990, 8:1293-1296.
7. Schulman KA, Yabroff KR: Measuring the cost-effectiveness of cancer care. Oncolology 1995, 9:523-537. This review article provides the groundwork for the methodology of cost-effectiveness analysis by a leader in the field.
8. Drummond MF, Stoddart GL: Economic analysis and clinical trial. Control Clin Trials 1984, 5:115-128.
9. Drummond MF: Guidelines for pharmoeconomic studies: the ways forward. Pharmacoeconomics 1994, 6:493-497.
10. Manning WG, Keeler EB, Newhouse JP, Sloss EM, Wasserman J: The taxes of sin. Do smokers and drinkers pay their way? JAMA 1989, 261:1604-1609.
11. Koopmanschap MA, van Roijen L, Bonneux L, Barendregt JJ: Current and future costs of cancer. Eur J Cancer 1994, 30A:60-65.
12. Riley GF, Potosky AL, Lubitz JD, Kessler LG: Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995, 33:828-841.
13. Rees GJG: Cost-effectiveness in oncology. Lancer 1985, ii:1405-1408.
14. Smith TJ, Hillner BE, Desch CE: Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993, 11:771-776.
15. Jaakkimainen L, Goodwin PJ, Pater J, Warde P, Murray N, Rapp E: Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial of non-small lung cancer. J Clin Oncol 1990, 8:1301-1309.
16. Goodwin PJ, Feld R, Evans WK, Pater J: Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell cancer. J Clin Oncol 1988, 6:1537-1547.
17. Smith TJ, Hillner BE, Neighbors DM, McSorley PA, le Chevalier T: Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol 1995, 13:2166-2173. This is the best example of an economic analysis to date in the context of a randomized trial. Unfortunately, the cost data were gathered retrospectively.
18. Richardson GE, Venzon DJ, Phelps R, Edison M, Brown M, Frame JN, Ihde DC, Johnson BE: Application of an algorithm for staging small-cell lung cancer can save one third of the initial evaluation costs. Arch Intern Med 1993, 153:329-337.
19. Evans WK: Management of metastatic non-small-cell lung cancer and a consideration of cost. Chest 1993, 103:68S-71S.
20. Rosenthal MA, Webster PJ, Gebski VJ, Stuart-Harris RC, Langlands AO, Boyages J: The cost of treating small cell lung cancer. Med J Aust 1992, 156:605-610.
21. Belani CP, Einarson TR, Arikian SR, Doyle J: Cost-effectiveness analysis of pleurodesis in the management of malignant pleural effusion. J Oncol Management 1995, 24-34.
22. Baker MS, Kessler LG, Urban N, Smucker RC: Estimating the treatment costs of breast and lung cancer [abstract]. Med Care 1991, 29:40-49.
23. Evans WK, Will BP, Wolfson MC, Gentleman JF, Berthelot J-M: An estimate of the cost-effectiveness of combined modality therapy for stage IIIa/IIIb NSCLC in Canada. Proc ASCO 1994, 13:1112.
24. Feld R, Pater J, Coodwin PJ, Grossman R, Coy P, Murray N: The restaging of responding patients with limited small cell lung cancer: is it really useful? Chest 1993, 103:1010-1016.
25. Coy P, Schaafsma J, Schofield JA, Nield JA: Comparative costs of lung cancer management. Clin Invest Med 1994, 17:577-587.
26. Health Services Commission: Prioritization of health services: a report to the Governor and Legislature. Oregon Health Services Commission; 1991:1-77.
27. Eddy DM: Clinical decision making: from theory to practice. JAMA 1991, 265:105-108.
28. Bennett CL, Smith TJ, George SL, Hillner BE, Fleishman S, Niell HB: Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials. J Clin Oncol 1995, 13:2457-2463.
29. Nichols CR, Fox EP, Roth BJ, Williams SD, Loehrer PJ, Einhorn LH: Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol 1994, 12:1245-1250.
30. Smith TJ, Desch CE, Hillner BH: Ways to reduce the cost of oncology care without compromising the quality. Cancer Invest 1994, 12:257-265.
31. Findlay M: Palliative chemotherapy can be cost-effective. Clin Oncol Alert 1995, 10:49-50.
32. Drummond MF, Davies L: Economic analysis alongside clinical trials: revisiting the methodologic issues. Int J Technol Assess Health Care 1991, 7:561-563.
33. Patton MD, Katterhagen JG: Cancer care critical pathways: implementing a successful program. Hosp Tech Feature Rep 1995, 14:1-49.
34. Stanfill PH: Cost-efficiencies in the oncology program strategies for survival. J Oncol Management 1995, 18-25.
35. Weeks JC, Yeap BY, Canellos GP, Shipp MA: Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 1991, 9:1196-1203.
36. GIVIO investigators: Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. JAMA 1994, 271:1587-1592.
37. Kagan AR: Routine imaging studies for the posttreatment surveillance of breast and colorectal carcinoma. J Clin Oncol 1991, 9:837-842.
38. Moertel CG, Felming TR, Macdonald JS, Haller DG, Laurie JA, Tangen C: An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993, 270:943-947.
39. Task Force on Principles for Economic Analysis of Health Care Technology: Economic analysis of health care technology: a report on principles. Ann Intern Med 1995, 122:61-70. This is an important article describing the principles and practices of economic analyses. Because economic analyses frequently are supported by manufacturers, there is a high risk for bias.